CS
MLTX icon

Candriam SCA’s MoonLake Immunotherapeutics MLTX Stock Holding History

Candriam SCA’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.2M Buy
818,126
+683,797
+509% +$11.3M 0.08% 226
2025
Q4 		$1.77M Buy
134,329
+687
+0.5% +$8.11K 0.01% 518
2025
Q3 		$958K Sell
133,642
-11,188
-8% -$583K 0.01% 583
2025
Q2 		$6.84M Sell
144,830
-29,690
-17% -$1.21M 0.04% 306
2025
Q1 		$6.82M Sell
174,520
-52,956
-23% -$2.28M 0.04% 280
2024
Q4 		$12.3M Sell
227,476
-11,524
-5% -$588K 0.07% 234
2024
Q3 		$12M Hold
239,000
– – 0.07% 246
2024
Q2 		$10.5M Hold
239,000
– – 0.06% 250
2024
Q1 		$12M Buy
239,000
+54,000
+29% +$2.93M 0.08% 236
2023
Q4 		$11.2M Buy
+185,000
New +$9.53M 0.08% 236

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return